Pharmaceutical News

RSS

Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer

A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients.

9 Dec 2011

ZEN bust-enhancing supplements may increase risk of breast cancer

Women who use bust-enhancing dietary supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring toxin that widely contaminates agricultural products, could be increasing their risk of breast cancer. That is the warning from breast health experts in a paper published online ahead of print publication in the January issue of IJCP, the International Journal of Clinical Practice.

9 Dec 2011

First Edition: December 9, 2011

Today's early morning highlights from the major news organizations include artilces about a new GOP tax plan that includes a Medicare pay fix for doctors and President Obama's support of a decision to keep the "Morning After Pill" from minors.

9 Dec 2011

Sebelius overrules FDA on 'morning after' pill's OTC availability

The decision to keep the contraceptive pill "Plan B" behind the counter could shield the Obama administration from a bruising battle with conservatives but comes at the expense of liberal groups who are "shocked" at the decision.

9 Dec 2011

Experimental sublingual vaccine shows promise against influenza infection

Scientists from the International Vaccine Institute (IVI) have discovered that an antigen common to most influenza viruses, and commonly referred to as matrix protein 2 (M2), when administered under the tongue could protect mice against experimental infection caused by various influenza viruses, including the highly pathogenic avian H5 virus and the pandemic H1 ("swine flu") virus.

9 Dec 2011

Dramatic rise in substance abuse treatment admission rates from 1999-2009

A new report shows that while the overall rate of substance abuse treatment admissions among those aged 12 and older in the United States has remained nearly the same from 1999 to 2009, there has been a dramatic rise (430 percent) in the rate of treatment admissions for the abuse of prescription pain relievers during this period.

9 Dec 2011

Paper calls for strong steps to control global crisis of antibiotic-resistant infections

Shahriar Mobashery, a University of Notre Dame researcher, is one of the coauthors of a new paper by a group of the world's leading scientists in academia and industry that calls for strong steps to be taken to control the global crisis of antibiotic resistance in bacteria. The group issued a priority list of steps that need to be taken on a global scale to resolve the crisis.

9 Dec 2011

Gilead Sciences to donate $8M in visceral leishmaniasis drug to WHO

Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."

9 Dec 2011

caprotec's CCMS technology identifies novel co-targets of three anti-cancer drugs

caprotec bioanalytics GmbH announced today the discovery of previously unknown specific drug-protein interactions for several anti-cancer drugs and the identification of potential novel co-targets of the drug molecules through the use of company's CCMS technology.

9 Dec 2011

The Hormone Foundation publishes fact sheet about harmful hCG diet

In an effort to provide clarity to the confusion surrounding the human chorionic gonadotropin (hCG) diet, The Hormone Foundation, the public education affiliate of The Endocrine Society, today published, "Myth vs. Fact: The Human Chorionic Gonadotropin (hCG) Diet."

9 Dec 2011

Menarini, Moberg Derma partner to distribute Emtrix in Italy

Moberg Derma AB has entered into a distribution agreement with Menarini Group for Emtrix - for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.

9 Dec 2011

Pharmaceutical spam leads patients to seek out online information about prescription drugs

Spam advertising of pharmaceutical products is leading patients to seek out information about prescription drugs online, according to a report to be published in the International Journal Business and Systems Research. If those drugs are not available to the internet user through their physician there is a risk that they may obtain such products via illicit means.

9 Dec 2011

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according to research published in Cancer Cell today.

9 Dec 2011

USPTO issues Diabetes Patent to Omni Bio

Omni Bio Pharmaceutical, Inc. today announced that U.S. Patent No. 8,071,551, entitled "METHODS AND COMPOSITIONS FOR TREATING DIABETES," was issued by the United States Patent and Trademark Office on December 6, 2011. The Diabetes Patent expires in May 2022.

9 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

FDA advisory panel OKs anemia drug peginesatide

Once approved by the FDA, the once-monthly injection could capture a share of the $3 billion U.S. market for anemia drugs used for kidney dialysis patients, currently dominated by Amgen Inc's blockbuster Epogen. Affymax, which developed the drug with partner Takeda Pharmaceutical Co Ltd, is also expected to price its product below Epogen.

8 Dec 2011

Zoledronic acid increases bone mineral density, reduces recurrence in postmenopausal breast cancer

The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial.

8 Dec 2011

Ixabepilone-sunitinib combination holds potential against chemotherapy-resistant ovarian cancer

The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.

8 Dec 2011

BCX4945 proves effective at clearing malaria infections

An antimalarial agent developed by researchers at Albert Einstein College of Medicine of Yeshiva University proved effective at clearing infections caused by the malaria parasite most lethal to humans - by literally starving the parasites to death. The novel research, carried out on a small number of non-human primates, could bolster efforts to develop more potent therapies against one of the world's leading killers.

8 Dec 2011

Ecstasy drug associated with chronic changes in human brain

Recreational use of Ecstasy - the illegal "rave" drug that produces feelings of euphoria and emotional warmth - is associated with chronic changes in the human brain, Vanderbilt University investigators have discovered.

8 Dec 2011

Pharmaceutical News

Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer

ZEN bust-enhancing supplements may increase risk of breast cancer

First Edition: December 9, 2011

Sebelius overrules FDA on 'morning after' pill's OTC availability

Experimental sublingual vaccine shows promise against influenza infection

Dramatic rise in substance abuse treatment admission rates from 1999-2009

Paper calls for strong steps to control global crisis of antibiotic-resistant infections

Gilead Sciences to donate $8M in visceral leishmaniasis drug to WHO

caprotec's CCMS technology identifies novel co-targets of three anti-cancer drugs

The Hormone Foundation publishes fact sheet about harmful hCG diet

Menarini, Moberg Derma partner to distribute Emtrix in Italy

Pharmaceutical spam leads patients to seek out online information about prescription drugs

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

USPTO issues Diabetes Patent to Omni Bio

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

FDA advisory panel OKs anemia drug peginesatide

Zoledronic acid increases bone mineral density, reduces recurrence in postmenopausal breast cancer

Ixabepilone-sunitinib combination holds potential against chemotherapy-resistant ovarian cancer

BCX4945 proves effective at clearing malaria infections

Ecstasy drug associated with chronic changes in human brain

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News